V. Pirriatore

Undetectable antimicrobial plasma concentrations in an HIV-positive patient with protein-losing enteropathy and chylothorax during Mycobacterium genavense and Leishmania abdominal infections

G. di Perri, A. Calcagno, I. Motta, 2018, The Journal of antimicrobial chemotherapy.

Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting.

G. di Perri, A. Calcagno, G. Cenderello, 2017, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Latent tuberculosis infection screening in persons newly-diagnosed with HIV infection in Italy: a multicentre study promoted by the Italian Society of Infectious and Tropical Diseases.

A. Giannetti, A. Antinori, A. Calcagno, 2019, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Rifampicin and Isoniazid Maximal Concentrations are Below Efficacy-associated Thresholds in the Majority of Patients: Time to Increase the Doses?

G. di Perri, A. Calcagno, I. Motta, 2021, International journal of antimicrobial agents.

The Manifesto of Pharmacoenosis: Merging HIV Pharmacology into Pathocoenosis and Syndemics in Developing Countries

G. di Perri, A. Calcagno, B. Castelnuovo, 2021, Microorganisms.

Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid

G. di Perri, A. Calcagno, A. de Nicolò, 2018, The Journal of antimicrobial chemotherapy.

Presence of EBV DNA in Cerebrospinal Fluid is Associated with Greater HIV RNA and Inflammation.

S. Gianella, T. Lupia, G. di Perri, 2019, AIDS.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Correlations between cerebrospinal fluid biomarkers, neurocognitive tests, and resting-state electroencephalography (rsEEG) in patients with HIV-associated neurocognitive disorders

G. Noce, G. Stroffolini, G. di Perri, 2022, Journal of NeuroVirology.

Epstein-Barr Virus May Contribute to Central Nervous System Involvement in HIV-positive Individuals

T. Lupia, G. di Perri, A. Calcagno, 2018, bioRxiv.

HIV-1 detection in the olfactory mucosa of HIV-1-infected participants

P. Cassoni, G. di Perri, A. Calcagno, 2019, AIDS.

Changes in Cerebrospinal Fluid, Liver and Intima-media-thickness Biomarkers in Patients with HIV-associated Neurocognitive Disorders Randomized to a Less Neurotoxic Treatment Regimen

G. Stroffolini, A. Calcagno, M. Trunfio, 2023, Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology.

Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting.

G. di Perri, A. Calcagno, G. Cenderello, 2017, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.